Drugs Made In America Acquisition Corp. (DMAA) Form 8-K — Oct 21, 2026
$DMAAForm 8-KItems 1.01, 8.01, 9.01Filed Oct 21, 2026, 5:27 PM ET0001213900-26-111421Original filing
Drugs Made In America Acquisition Corp. amended its merger agreement with Power Analytics Global Corp, adding a Reversion Event that automatically cuts the deal's Closing Valuation from $2.85 billion to $1.71 billion if PAGC's acquisition of APQC Inc is not completed by November 1, 2026. After a Reversion Event, the APQC completion condition and the SPAC's right to terminate if the deal fails by December 31, 2026 are deleted, though APQC and other assets may later be added back at independently appraised value, capped at $2.85 billion total.
Key figures
- Valuation ceiling usd
- 2850000000
- Apqc acquisition deadline
- 2026-11-01
- Fairness opinion expected by
- 2026-10-26
- Original closing valuation usd
- 2850000000
- Standalone closing valuation usd
- 1710000000
- Termination right deadline if apqc incomplete
- 2026-12-31
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.